Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation

Circulation

Volumn 103, Issue 18, 2001, Pages 2248-2253

  Undas, Anetta ^a   Brummel, Kathleen E ^b   Musial, Jacek ^a   Mann, Kenneth G ^b   Szczeklik, Andrew ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Factor V; Factor XIII; Fibrinogen; Simvastatin; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; FIBRINOPEPTIDE A; FIBRINOPEPTIDE B; PROTHROMBIN; SIMVASTATIN;

ADULT; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 0035826856     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.18.2248     Document Type: Article

References (28)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999; 282:2340-2346.
2. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
3. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J. 2000;139:577-583.
4. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
5. Di Garbo V, Cordova R, Avellone G. Increased thrombin generation and complement activation in patients with type II hyperlipoproteinemia: effects of simvastatin treatment. Curr Ther Res. 1997;58:706-723.
6. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol. 1999;33:1286-1293.
7. Dangas G, Smith DA, Unger AH, et al. Pravastatin. an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost. 2000;83:688-692.
8. Mann KG. The coagulation explosion. Ann N Y Acad Sci. 1994;714: 265-269.
9. Esmon CT, Ding W, Yasuhiro K, et al. The protein C pathway: new insights. Thromb Haemost. 1997;78:70-74.
10. Lorand L, Jeong JM, Radek JT, et al. Human plasma factor XIII: subunit interactions and activation of zymogen. Methods Enzymol. 1993;222:22-35.
11. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 1997;17:265-272.
12. Ferro D, Basili S, Alessandri C, et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis. 2000;149:111-116.
13. Rand MD, Lock JB, van't Veer C, et al. Blood clotting in minimally altered whole blood. Blood. 1996;88:3432-3445.
14. McDuffie FC, Giffin C, Niedringhaus R, et al. Prothrombin, thrombin and prothrombin fragments in plasma of normal individuals and of patients with laboratory evidence of disseminated intravascular coagulation. Thromb Res. 1979;16:759-773.
15. Foster WB, Tucker MM, Katzmann JA, et al. Monoclonal antibodies to human coagulation factor V and factor Va. Blood. 1983;61:1060-1067.
16. Thorngren M, Shafi S, Born GVR. Thromboxane A2 in skin bleeding time blood and in clotting blood before and after administration of acetylosalicylic acid. Lancet. 1983;1:1075-1084.
17. Szczeklik A, Krzanowski M, Gora P, et al. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992;80:2006-2011.
18. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
19. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979;76:4350-4354.
20. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. J Biol Chem. 1999;274:22862-22870.
21. Hockin MF, Kalafatis M, Shatos M, et al. Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17:2765-2775.
22. Weiss JH, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood. 1988;71:629-635.
23. Hatton MWC, Moar SL, Richardson M. Enhanced binding of fibrinogen by the endothelium after treatment of the rabbit aorta with thrombin. J Lab Clin Med. 1990;115:356-364.
24. Butenas S, van't Veer C, Mann KG. Evaluation of the initial phase of blood coagulation using ultrasensitive assays for serine protease. J Biol Chem. 1997;272:21527-21533.
25. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood. 1999;94:2169-2178.
26. Tracy PB, Nesheim ME, Mann KG. Proteolytic alterations of factor Va bound to platelets. J Biol Chem. 1983;258:662-669.
27. Suzuki K, Nishioka J, Hayashi T, et al. Functionally active thrombomodulin is present in human platelets. J Biochem. 1988;104:628-633.
28. Fenton JW II, Shen GX, Minnear FL, et al. Statins induce hypothrombotic states? Clin Appl Thromb Hemost. 2000;6:18-21.